Find clinical trials | Bayside Health (Alfred)

AC220-167

A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients with Newly Diagnosed FLT3-ITD + Acute Myeloid Leukemia in Complete Remission [Comparison of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD + Acute Myeloid Leukemia Patients in Complete Remission] (NCT06824168)

This clinical two-arm trial is designed to evaluate two doses of quizartinib (30mg/day or 60mg/day) as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute myeloid leukemia (AML) in first complete remission (CR) who have not received allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Currently recruiting

ACE-DOUBLE

Dilation Optimisation for Uniform Bioprosthetic Leaflet Expansion: The ACE-DOUBLE Trial (NCT07430267)

The goal of this clinical trial is to discover if routine 'double tap' balloon post-dilation improves valve expansion and clinical outcomes in adults undergoing Transcatheter Aortic Valve Implantation (TAVI) with the SAPIEN balloon-expandable TAVI prosthesis. The primary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve expansion. The secondary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve haemodynamic performance. Participants will be randomised to balloon-expandable TAVI either with or without routine 'double tap' balloon post-dilation.

Currently recruiting

ACEMID

Australian Centre of Excellence in Melanoma Imaging & Diagnosis (ACEMID) Cohort Study (ACTRN12619001706167)

Currently recruiting

Actair study

Patient Stratification and Monitoring of ACTAIR® Treatment Efficacy Using New Objective Immune Markers (Trial Not Registered)

Investigated initiated study - prospective controlled (three-arm) trial of 18 months of Actair (extended to 36 months total) whereby patients who had a clinical history of perennial rhinitis confirmed with a HDM skin prick of >5mm and serum HDM specific IgE > class 3 were recruited. Now a further extension of the study has been approved to include patients who are currently receiving a licensed house dust mite sublingual immunotherapy tablet (Actair or Acarizax) treatment for 2 or 3 years.

Currently recruiting

ADAPT-TDM

A beta-lactam antibiotic Dose Adaptation Pilot randomised controlled Trial utilising Therapeutic Drug Monitoring (ADAPT-TDM) (ACTRN12623000032651)

Currently recruiting

ADOPT-LUNG ETOP 25-23

An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC (ACTRN12624001373561)

No longer recruiting

ADR

Australasian Dermatology Registry (Trial Not Registered)

The Australasian Dermatology Registry captures real world data to enable monitoring and surveillance of current and emerging treatments and provides a platform for dermatology research, helping dermatologists provide the best care to their patients. The Australasian Dermatology Registry is a national collaboration between dermatologists, facilitated and coordinated by the Skin Health Institute.

Currently recruiting

ADVANCE-extension

A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION (ADVANCE-extension) (NCT03683186)

No longer recruiting

ADVANCE-outcomes

A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients (ADVANCE-outcomes) (NCT03626688)

No longer recruiting

AF and sexual dysfunction

Assessing the impact of atrial fibrillation and catheter ablation on sexual function: an observational study (Trial Not Registered)

This study aims to ask patients about how their AF has affected intimate relationships and whether catheter ablation has any effect on this.

Currently recruiting

AFFINE

Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C<=1%) (NCT04370054)

No longer recruiting

AFMR_TTE

Outcomes of Surgery for Atrial Functional Mitral Regurgitation (ACTRN12624000705583)

No longer recruiting

AHSCT in MS

A Phase II observational study: autologous haematopoietic stem cell transplantation for highly active treatment resistant multiple sclerosis (ACTRN12616000151437)

Currently recruiting

AIRPORT

Amino acid Infusion to improve Renal outcomes after Pulmonary Organ Transplantation [AIRPORT Study] (ACTRN12625001381471)

Acute kidney injury (AKI) occurs in two-thirds of patients after lung transplantation, even in patients who usually have normal kidney function. Amino acids are the 'building blocks' of protein and can be given as nutritional supplements. More recently they have been shown to be effective in preventing kidney damage in cardiac surgery. We think they may also help in lung transplantation by improving renal blood flow, which is why we are carrying out this study. Synthamin-17 is a liquid medicine that contains amino acids which can be given into veins as a form of nutritional supplement in patients who can't absorb proteins from the gut.

Coming soon

AK-US-001-0105 - NASH

A Phase 3, Randomized, Double-blind, Placebo-controlled study evaluating the safety and efficacy of efruxifermin in subjects with non-cirrhotic nonalcoholic steatohepatitis (NASH) and fibrosis. (NCT06215716)

Currently recruiting

AK-US-001-0106

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis [NASH]/Metabolic Dysfunction-Associated Steatohepatitis [MASH] (NCT06528314)

Currently recruiting

ALLAY-HFrEF

Safety and Efficacy of the Alleviant No-Implant Interatrial Shunt in Patients with Heart Failure and Reduced Ejection Fraction (NCT06812533)

This study is to evaluate the safety and efficacy of the Alleviant ALV1 System in patients with reduced ejection fraction (HFrEF), who remain symptomatic despite optimal maximally tolerated guideline directed medical therapy (GDMT).

Currently recruiting

Alpha Orbit - STAR0215-301

A Phase 3, Multicenter, randomised, double-blind, placebo controlled trial to evaluate the efficacy and safety of Navenibart in participants with Hereditary Angioedema (NCT06842823)

Navenibart is being developed as a prophylactic treatment for the prevention of Hereditary Angioedema attacks.

No longer recruiting

Alpha-9 GRPR Study

A Phase 1 Study Investigating the Safety, Tumor Uptake, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors (ACTRN12625000268448)

A study is testing a new diagnostic product, to detect tumour tissue throughout the body using a radioactive substance a positron emission tomography (PET) tracer, that targets a protein Gastrin-Releasing Peptide Receptor (GRPR) which is found in various cancer types. This is not a treatment study. No treatment will be provided to you as part of this study. This study is testing a new imaging product only.

Currently recruiting

ALTER

Angiotensin II in lung transplantation to improve renal and respiratory outcomes - a feasibility study [the ALTER-outcomes feasibility study] (ACTRN12625001374459)

Low blood pressure is very common after lung transplant surgery, even in patients who normally have high blood pressure. Angiotensin-II is a synthetic equivalent to a naturally occurring chemical in your own body that increases blood pressure. In some studies of participants given angiotensin II, those who were given angiotensin-II had evidence to suggest improved kidney health outcomes.

Coming soon